Uncategorized

RELIEF THERAPEUTICS Holding SA announced the Annual General Meeting of shareholders will take place Tues., June 20, 2023 at 9 a.m. CEST at avenue de Sécheron 15 in Geneva, near the Relief Therapeutics offices.

Innate Pharma SA announced that the abstract entitled “A first-in-human study of CD123 NK Cell Engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia” was published on the ASCO 2023 Annual Meeting website.

Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive opinion for the use of Veklury® in COVID-19 patients with severe renal impairment, including those on dialysis.

Genexine announced the publication of an abstract of its phase 2 clinical trial on triple combination neoadjuvant therapy for HNSCC in the ASCO.

Invitae, a leading medical genetics company, announced that Chief Financial Officer Yafei Wen is resigning to pursue other opportunities, effective June 30, 2023.

Ascentage Pharma announced that 4 of its abstracts were selected for presentations at the 2023 American Society of Clinical Oncology Annual Meeting.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced two poster presentations at the 2023 American Association of Clinical Oncology annual meeting to be held in Chicago, IL.

Antengene Corporation Limited announced that the latest results from the Phase I/II TORCH-2 study will be presented as a poster at the 2023 American Society for Clinical Oncology Annual Meeting taking place from June 2nd to 6th, 2023 at the McCormick Place Convention Center in Chicago, IL.

Sobre el secreto de los buenos especialistas y su capacidad comunicativa

The Massachusetts-based biopharma became the second company this week to drop its amyotrophic lateral sclerosis hopeful after it failed to elicit significant improvement compared with placebo.